Lundbeck

Overview

Danish neurology-focused pharmaceutical company serving 10 million daily patients, transitioning from pure small-molecule CNS development to biotherapeutics including bispecifics, blood-brain barrier shuttles, and oligonucleotides via full CMO outsourcing. Lundbeck serves 10 million patients daily in neurology, neurorare, and neuro-adjacent therapeutic areas, and entered the biotherapeutics space approximately five years ago via acquisition of a Seattle-area company (Alder BioPharmaceuticals), gaining a migraine therapeutic. Lundbeck's biologics pipeline has expanded beyond monoclonal antibodies to include bispecific antibodies, a blood-brain barrier shuttle technology entering the clinic, and oligonucleotides, all currently manufactured through full CMO outsourcing. (Segment 2 (05:00-10:00))